1. Articles in category: Burden of Treatment

    1-24 of 108 1 2 3 4 5 »
    1. Long-term inpatient disease burden in the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study: A cohort study of 21,297 childhood cancer survivors.

      Long-term inpatient disease burden in the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study: A cohort study of 21,297 childhood cancer survivors.

      PLoS Med. 2017 May;14(5):e1002296

      Authors: de Fine Licht S, Rugbjerg K, Gudmundsdottir T, Bonnesen TG, Asdahl PH, Holmqvist AS, Madanat-Harjuoja L, Tryggvadottir L, Wesenberg F, Hasle H, Winther JF, Olsen JH, ALiCCS study group

      Read Full Article
    2. Clinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma.

      Clinical and biological features of neuroblastic tumors: A comparison of neuroblastoma and ganglioneuroblastoma.

      Oncotarget. 2017 Apr 17;:

      Authors: He WG, Yan Y, Tang W, Cai R, Ren G

      Abstract Neuroblastoma (NB), ganglioneuroblastoma intermixed (GNBi) and ganglioneuroblastoma nodular (GNBn) are neuroblastic tumors that present with a wide range of symptoms and variable prognoses.

      Read Full Article
      Mentions: MYCN NSE
    3. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

      A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

      Int J Cancer. 2017 Jan 15;140(2):480-484

      Authors: Kushner BH, Cheung NV, Modak S, Becher OJ, Basu EM, Roberts SS, Kramer K, Dunkel IJ

      Read Full Article
      Mentions: MYCN
    4. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)

      The c-Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c-Met receptor tyrosine kinase. A phase 1 and pharmacokinetic (PK) trial evaluating tivantinib was conducted in children with relapsed/refractory solid tumors.

      Read Full Article
      Mentions: COG Refractory
    5. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.

      Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.

      Pediatr Blood Cancer. 2017 Apr 24;:

      Authors: Mody R, Zhao L, Yanik GA, Opipari V

      Abstract PURPOSE: Prognosis for relapsed/refractory high-risk neuroblastoma (HR-NBL) remains poor. Bortezomib, a proteasome inhibitor, has shown preclinical activity against NBL as a single agent and in combination with cytotoxic chemotherapy including irinotecan.

      Read Full Article
    6. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma

      Prognosis for relapsed/refractory high-risk neuroblastoma (HR-NBL) remains poor. Bortezomib, a proteasome inhibitor, has shown preclinical activity against NBL as a single agent and in combination with cytotoxic chemotherapy including irinotecan.

      Eighteen HR-NBL patients with primary refractory (n = 8) or relapsed (n = 10) disease were enrolled in a Phase I study using modified Time To Event Continual Reassessment Method.

      Read Full Article
    7. In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

      In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.

      Drug Deliv Transl Res. 2017 Apr 21;:

      Authors: Gilabert-Oriol R, Chernov L, Anantha M, Dragowska WH, Bally MB

      Abstract Topotecan is a drug that is under investigation for the treatment of neuroblastoma and has been encapsulated into liposomes to improve its therapeutic efficacy.

      Read Full Article
      Mentions: Treatment
    8. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

      A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.

      Clin Cancer Res. 2017 Apr 21;:

      Authors: Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, Marabelle A, Pearson ADJ, Modak S, Cash T, Robinson GW, Motta M, Matano A, Bhansali SG, Dobson JR, Parasuraman S, Chi SN

      Read Full Article
    9. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Cochrane Database Syst Rev. 2017 Apr 21;4:CD010349

      Authors: Kraal KC, van Dalen EC, Tytgat GA, Van Eck-Smit BL

      Abstract BACKGROUND: Patients with newly diagnosed high-risk (HR) neuroblastoma (NBL) still have a poor outcome, despite multi-modality intensive therapy.

      Read Full Article
      Mentions: MIBG
    10. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

      Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

      Exp Biol Med (Maywood). 2017 Jan 01;:1535370217706952

      Authors: Cooper JP, Reynolds CP, Cho H, Kang MH

      Abstract Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells.

      Read Full Article
    11. Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567

      Authors: McGinty L, Kolesar J

      Abstract PURPOSE: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.

      Read Full Article
      Mentions: Treatment
    12. Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.

      Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.

      Mol Ther. 2017 Mar 21;:

      Authors: Fisher J, Abramowski P, Wisidagamage Don ND, Flutter B, Capsomidis A, Cheung GW, Gustafsson K, Anderson J

      Abstract Chimeric antigen receptors (CARs) combine T cell activation with antibody-mediated tumor antigen specificity, bypassing the need for T cell receptor (TCR) ligation.

      Read Full Article
      Mentions: Antibody
    13. Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

      Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

      Mol Ther Oncolytics. 2017 Mar 17;4:67-76

      Authors: Gutova M, Goldstein L, Metz M, Hovsepyan A, Tsurkan LG, Tirughana R, Tsaturyan L, Annala AJ, Synold TW, Wan Z, Seeger R, Anderson C, Moats RA, Potter PM, Aboody KS

      Read Full Article
    14. ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      Scientists from The Institute of Cancer Research, London, have been awarded £1.5 million by the charity Children with Cancer UK to advance precision medicine in the UK and improve cancer treatment for children and young adults.

      Read Full Article
      Mentions: Treatment
    15. P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.

      P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.

      Int J Cancer. 2017 Mar 24;:

      Authors: Lopez-Barcons L, Maurer BJ, Kang MH, Reynolds CP

      Abstract We previously reported that concurrent ketoconazole, an oral anti-fungal agent and P450 enzyme inhibitor, increased plasma levels of the cytotoxic retinoid, fenretinide (4-HPR) in mice.

      Read Full Article
    16. Epidemiological analysis of childhood cancer in Japan based on population-based cancer registries, 1993-2009.

      Epidemiological analysis of childhood cancer in Japan based on population-based cancer registries, 1993-2009.

      Jpn J Clin Oncol. 2017 Mar 17;:1-4

      Authors: Ishihara H, Ohno Y, Fujii M, Hara J, Soda M

      Abstract Background: There are few recent data on trends in childhood cancer incidence using population-based cancer registries in Japan. Methods: This study comprised 6110 reported cases of patients aged 0-14 years who were diagnosed as having primary cancer between 1993 and 2009.

      Read Full Article
    17. Topotecan-Vincristine-Doxorubicin in Stage 4 High Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid Cojec - a SIOPEN Study.

      Topotecan-Vincristine-Doxorubicin in Stage 4 High Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC - a SIOPEN Study.

      Cancer Res Treat. 2017 Mar 21;:

      Authors: Amoroso L, Erminio G, Makin G, Pearson AD, Brock P, Valteau-Couanet D, Castel V, Pasquet M, Laureys G, Thomas C, Luksch R, Ladenstein R, Haupt R, Garaventa A, SIOPEN Group

      Read Full Article
      Mentions: SIOPEN
    18. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Eur J Cancer. 2017 Mar 19;76:188-196

      Authors: Kraal KC, Bleeker GM, van Eck-Smit BL, van Eijkelenburg NK, Berthold F, van Noesel MM, Caron HN, Tytgat GA

      Read Full Article
      Mentions: GPOH MIBG
    19. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.

      Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.

      J Cancer Res Clin Oncol. 2017 Mar 11;:

      Authors: Cai J, Pan C, Tang Y, Chen J, Zhou M, Li B, Xue H, Shen S, Gao Y, Zhang A, Tang J

      Read Full Article
    20. Effects of a combined physical and psychosocial intervention program for childhood cancer patients on quality of life and psychosocial functioning: results of the QLIM randomized clinical trial.

      Effects of a combined physical and psychosocial intervention program for childhood cancer patients on quality of life and psychosocial functioning: results of the QLIM randomized clinical trial.

      Psychooncology. 2016 07;25(7):815-22

      Authors: van Dijk-Lokkart EM, Braam KI, van Dulmen-den Broeder E, Kaspers GJ, Takken T, Grootenhuis MA, Streng IC, Bierings M, Merks JH, van den Heuvel-Eibrink MM, Veening MA, Huisman J

      Read Full Article
    21. An Evidence-based Recommendation for a Standardized Approach to Detecting Metastatic Neuroblastoma in Staging Bone Marrow Biopsies.

      An Evidence-based Recommendation for a Standardized Approach to Detecting Metastatic Neuroblastoma in Staging Bone Marrow Biopsies.

      Pediatr Dev Pathol. 2017 Jan-Feb;20(1):38-43

      Authors: Parsons LN, Gheorghe G, Yan K, Simpson P, Jarzembowski JA

      Abstract Neuroblastoma is a common malignant tumor of childhood. Accurate bone marrow (BM) evaluation for metastatic tumor is essential; however, no standardized pathologic workup exists for staging BMs.

      Read Full Article
      Mentions: Staging Bone Marrow
    22. Simple dilute-and-shoot method for urinary vanillylmandelic acid and homovanillic acid by liquid chromatography tandem mass spectrometry.

      Simple dilute-and-shoot method for urinary vanillylmandelic acid and homovanillic acid by liquid chromatography tandem mass spectrometry.

      Clin Chim Acta. 2017 Mar 03;:

      Authors: Clark ZD, Cutler JM, Pavlov IY, Strathmann FG, Frank EL

      Abstract BACKGROUND: Neuroblastomas are pediatric tumors characterized by overproduction of catecholamines. The catecholamine metabolites, vanillylmandelic acid (VMA) and homovanillic acid (HVA), are used in clinical evaluation of neuroblastoma.

      Read Full Article
    1-24 of 108 1 2 3 4 5 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (2 articles) MYCN
    2. (1 articles) NSE